Dawn Sauro Appointed To Chief Operating Officer At Elligo Health

Appointments

Dawn Sauro appointed to Chief Operating Officer at Elligo Health

Elligo Health Research has announced that Dawn Sauro has been named Chief Operating Officer (COO), with the aim of furthering the company’s growth, efficiency and mission of optimising the intersection of healthcare and research through methods including new technology, custom research practice methods and direct access to patients.

Elligo Health is a healthcare-enabling research organisation that accelerates clinical trials and has access to over 150 million patients and their HIPAA-compliant healthcare data. Sauro has previously worked as executive vice president of Research Strategy at Elligo, and brings more than 30 years of drug and device development experience to her new role.

Before joining Elligo, Sauro worked as chief development officer at Clinpace Clinical Research (now known as Caidya), during this role she grew the organisation so it became a trusted partner for various sponsors across a range of therapy areas.

Commenting on Sauro’s appointment, Elligo’s CEO John Potthoff, said “Dawn is a drug development and clinical research business leader with deep subject matter expertise across a broad spectrum of therapeutic areas, but specifically brings vast knowledge in haematology and oncology. She is a valued member of company leadership with decades of industry insight, client relationships and an understanding of unique needs that help sponsors and clinical research sites drive results.”

Sauro added: “I look forward to continuing in this new leadership role with Elligo, but also continuing to focus on delivering outcomes that move us all closer to our ultimate goal – providing everyone with easier access to participate in clinical research.”

Alfonso Quintás-Cardama to join Foghorn Therapeutics as new chief medical officer

The biotechnology company foghorn therapeutics has announced the addition of the new chief medical officer, Alfonso Quintás-Cardama, who will be replacing Sam Agresta after his retirement on 11 September 2023.

Helmholtz Centre for Infection Research appoints Josef Penninger to new scientific director

The Helmholtz Centre for Infection Research (HZI), Germany, has appointed professor Josef Penninger as scientific director.

Olav Hellebø to join Cytovation’s board of directors

Cytovation, a clinical stage immune-oncology company with a focus on targeted tumour membrane immunotherapies, has announced that it has appointed Olav Hellebø to its board of directors.

Alfonso Quintás-Cardama to join Foghorn Therapeutics as new chief medical officer

Helmholtz Centre for Infection Research appoints Josef Penninger to new scientific director

Olav Hellebø to join Cytovation’s board of directors

Reacta appoints Kevin Hawkins as new head of regulatory affairs

Simon Sinclair appointed as chief medical officer of Ondine Biomedical

Pharmafocus

Categories

Social Footprints